The Fate of Effector CD8 T Cells in Vivo is Controlled by the Duration of Antigen Stimulation

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2006 Jul 11

PMID 16827897

Citations 8

Authors

Xiaopei Huang

Yiping Yang

Affiliations

Soon will be listed here.

Abstract

What controls the fate of the T-cell response remains incompletely defined. Gain of effector function facilitated by costimulation has been thought to be a crucial factor in determining the outcome of the T-cell response, i.e. long-term memory in the presence of costimulation versus tolerance induction in the absence of costimulation. In this study, we show that while costimulation or cognate CD4 helps to promote the acquisition of effector function during the initial phase of the CD8 T-cell response, the fate of effector CD8 T cells is controlled by the duration of subsequent antigenic stimulation. Effector CD8 T cells differentiate into memory cells only after clearance of antigen, whereas in the presence of persistent antigen, effector CD8 T cells are tolerized. Furthermore, protective immunity against tumour cannot develop in the persisting antigen environment. These results suggest that removal of persisting antigen by other means might be a prerequisite for effective immunotherapy in cancer.

Citing Articles

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.

Lin C, Levy P, Alflen A, Apriamashvili G, Ligtenberg M, Vredevoogd D Cancer Cell. 2024; 42(4):623-645.e10.

PMID: 38490212 PMC: 11003465. DOI: 10.1016/j.ccell.2024.02.016.

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures.

Elliot T, Lecky D, Bending D Essays Biochem. 2023; 67(6):967-977.

PMID: 37386922 PMC: 10539945. DOI: 10.1042/EBC20220247.

Tumor reductive therapies and antitumor immunity.

Guo H, Tsung K Oncotarget. 2017; 8(33):55736-55749.

PMID: 28903456 PMC: 5589695. DOI: 10.18632/oncotarget.18469.

In situ vaccine, immunological memory and cancer cure.

Tsung K, Norton J Hum Vaccin Immunother. 2015; 12(1):117-9.

PMID: 26360526 PMC: 4962727. DOI: 10.1080/21645515.2015.1073427.

Allospecific CD4(+) effector memory T cells do not induce graft-versus-host disease in mice.

Zhang P, Wu J, Deoliveira D, Chao N, Chen B Biol Blood Marrow Transplant. 2012; 18(10):1488-99.

PMID: 22809867 PMC: 3443280. DOI: 10.1016/j.bbmt.2012.07.009.

References

Schwartz R . Models of T cell anergy: is there a common molecular mechanism?. J Exp Med. 1996; 184(1):1-8. PMC: 2192660. DOI: 10.1084/jem.184.1.1. View

Dittmer U, He H, Messer R, Schimmer S, Olbrich A, Ohlen C . Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity. 2004; 20(3):293-303. DOI: 10.1016/s1074-7613(04)00054-8. View

Morgan D, Liblau R, Scott B, Fleck S, McDevitt H, Sarvetnick N . CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol. 1996; 157(3):978-83. View

Cella M, Scheidegger D, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996; 184(2):747-52. PMC: 2192696. DOI: 10.1084/jem.184.2.747. View

Yang Y, Wilson J . CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996; 273(5283):1862-4. DOI: 10.1126/science.273.5283.1862. View

Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D . Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998; 95(3):1178-83. PMC: 18712. DOI: 10.1073/pnas.95.3.1178. View

He T, Zhou S, DA COSTA L, Yu J, Kinzler K, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5):2509-14. PMC: 19394. DOI: 10.1073/pnas.95.5.2509. View

Adler A, Marsh D, Yochum G, Guzzo J, Nigam A, Nelson W . CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med. 1998; 187(10):1555-64. PMC: 2212299. DOI: 10.1084/jem.187.10.1555. View

Kurts C, Heath W, Kosaka H, Miller J, Carbone F . The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 1998; 188(2):415-20. PMC: 2212451. DOI: 10.1084/jem.188.2.415. View

10.

Zajac A, Blattman J, Sourdive D, Suresh M, Altman J, Ahmed R . Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998; 188(12):2205-13. PMC: 2212420. DOI: 10.1084/jem.188.12.2205. View

11.

French R, Chan H, Tutt A, Glennie M . CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999; 5(5):548-53. DOI: 10.1038/8426. View

12.

Lee P, Yee C, Savage P, Fong L, Brockstedt D, Weber J . Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; 5(6):677-85. DOI: 10.1038/9525. View

13.

Bouillet P, Metcalf D, Huang D, Tarlinton D, Kay T, Kontgen F . Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999; 286(5445):1735-8. DOI: 10.1126/science.286.5445.1735. View

14.

Adler A, Huang C, Yochum G, Marsh D, Pardoll D . In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol. 2000; 164(2):649-55. DOI: 10.4049/jimmunol.164.2.649. View

15.

Steinman R, Turley S, Mellman I, Inaba K . The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000; 191(3):411-6. PMC: 2195815. DOI: 10.1084/jem.191.3.411. View

16.

Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P . Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000; 191(9):1499-512. PMC: 2213430. DOI: 10.1084/jem.191.9.1499. View

17.

Appay V, Nixon D, Donahoe S, Gillespie G, Dong T, King A . HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000; 192(1):63-75. PMC: 1887711. DOI: 10.1084/jem.192.1.63. View

18.

Zinkernagel R . Localization dose and time of antigens determine immune reactivity. Semin Immunol. 2000; 12(3):163-71; discussion 257-344. DOI: 10.1006/smim.2000.0253. View

19.

Xiong Y, Luscher M, Altman J, Hulsey M, Robinson H, Ostrowski M . Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol. 2001; 75(6):3028-33. PMC: 115931. DOI: 10.1128/JVI.75.6.3028-3033.2001. View

20.

Huang X, Yang Y . Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigen. Eur J Immunol. 2004; 34(5):1351-60. DOI: 10.1002/eji.200324734. View